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ABSTRACT
Proinflammatory cytokines contribute to renal injury, but the downstream effectors within kidney cells
are not well understood. One candidate effector is Klotho, a protein expressed by renal cells that has
antiaging properties; Klotho-deficient mice have an accelerated aging-like phenotype, including vascular
injury and renal injury. Whether proinflammatory cytokines, such as TNF and TNF-like weak inducer of
apoptosis (TWEAK), modulate Klotho is unknown. In mice, exogenous administration of TWEAK de-
creased expression of Klotho in the kidney. In the setting of acute kidney injury induced by folic acid, the
blockade or absence of TWEAK abrogated the injury-related decrease in renal and plasma Klotho levels.
TWEAK, TNF, and siRNA-mediated knockdown of IB all activated NFB and reduced Klotho
expression in the MCT tubular cell line. Furthermore, inhibition of NFB with parthenolide prevented
TWEAK- or TNF-induced downregulation of Klotho. Inhibition of histone deacetylase reversed TWEAK-
induced downregulation of Klotho, and chromatin immunoprecipitation showed that TWEAK promotes
RelA binding to the Klotho promoter, inducing its deacetylation. In conclusion, inflammatory cytokines,
such as TWEAK and TNF, downregulate Klotho expression through an NFB-dependent mechanism.
These results may partially explain the relationship between inflammation and diseases characterized by
accelerated aging of organs, including CKD.
J Am Soc Nephrol 22: 1315–1325, 2011. doi: 10.1681/ASN.2010101073
Acute kidney injury (AKI) and progressive loss of
renal function are associated with interstitial in-
flammation and tubular injury.1 Members of the
TNF superfamily of cytokines are key mediators of
renal injury, and the transcription factor nuclear
factor-kappaB (NFB) is a mediator of their bio-
logic activity.2–4 TNF has pleiotropic actions on
glomerular and tubular cells that contribute to re-
nal damage.5,6 More recently, TNF-like weak in-
ducer of apoptosis (TWEAK, TNFSF12) was iden-
tified as a mediator of kidney tubulointerstitial
inflammation through interaction with its receptor
Fn14.7,8 During kidney injury TWEAK may have
additional actions, not shared with TNF, such as
noncanonical activation of NFB resulting in ex-
pression of CCL21.9 Both TWEAK and TNF may
promote tubular cell injury and death.8,10 Cell death
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contributes to tubular cell loss in both AKI and chronic kid-
ney disease (CKD).11 In addition, TNF and TWEAK are
mediators of inflammation and atherosclerosis, which are
key events in CKD patients exhibiting high mortality
rates.12–14 In fact, CKD has features consistent with acceler-
ated aging such as accelerated atherosclerosis. -Klotho or
Klotho is a kidney-secreted hormone with antiaging prop-
erties.15,16 Klotho is a pleiotropic protein with glucuroni-
dase activity that modulates calcium transport by TRPV5,1
serves as a necessary coreceptor for fibroblast growth factor
23 (FGF23),17 regulating Pi homeostasis,18 inhibits Wnt sig-
naling,19 has antioxidant properties,20 and represses IGF-1
signaling.16
Klotho is downregulated during kidney
injury. Kidney Klotho mRNA is reduced in
long-term hypertension, diabetes mellitus,
andCKDmodels21 as well as in experimental
ischemia-reperfusion-induced AKI,22 and in
uremic hyperplastic parathyroid glands.23
Decreased expression of Klotho mRNA
and protein was confirmed in humans
with CKD.24 Because renal failure and in-
flammation are both associated with ac-
celerated aging features, such as vascular
injury and calcification, that are also ob-
served in Klotho knock-out (KO) mice,
we examined the relationship between
inflammation and Klotho expression.
The factors regulating Klotho expression
are poorly understood. LPS administration
decreased KlothomRNA, suggesting that the
expression of Klotho is modulated by acute
inflammatory stress in vivo.25 However, the
specific molecules that downregulated Klotho
could not be identified in cell culture experi-
ments. Angiotensin II downregulates Klotho
mRNA expression in tubular cells both in
culture and in vivo, but the intracellular mo-
lecular mechanisms were not addressed
in detail.26,27 Oxidative stress also down-
regulates Klotho.28,29 Statins and Rho ki-
nase inhibitors prevented angiotensin-in-
duced downregulation of Klotho in cultured
cells.27 Antioxidants, statins, and Rho kinase
inhibitors are known to prevent activation of
NFB in response to stimuli such as angio-
tensin II.30–32
Despite evidence relating inflammation to
low Klotho expression and to accelerated ag-
ing, there had been a poor understanding of
the inflammatory mediators that downregu-
late Klotho and of the intracellular mecha-
nisms involved.Arole forNFBhadnotbeen
characterized. We now report that TWEAK
and TNF promote the NFB-dependent
downregulationofKlothoexpression incultured tubular cells and
in the kidney in vivo.
RESULTS
Klotho mRNA and Protein Are Downregulated in
Acute Inflammatory Tubular Injury
Folic acid nephropathy is a model of AKI characterized by acute
renal failure and tubulointerstitial inflammation.7 In this AKI
model there is an increased renal expression of the inflammatory
cytokines belonging to the TNF superfamily—TWEAK and
TNF—andof their receptors: Fn14 forTWEAKandTNFR1and
Figure 1. Cytokine and Klotho expression in murine model of renal tubulointerstitial
inflammation. (A) Expression of inflammatory cytokines (TNF and TWEAK) and
TWEAK and TNF receptors (Fn14 and TNFR1/TNFR2, respectively) mRNA were mea-
sured by real time RT-PCR in kidneys of mice with AKI induced by a folic acid overdose
at 72 hours. Expression of cytokines and their receptors is increased in this model.
Mean  SEM of six animals per group. *P  0.05 versus control. (B) Representative
immunohistochemistry of renal macrophage infiltration at 72 hour AKI mice Macro-
phages were identified by staining with F4/80 antibody. Increased macrophage-
positive cells were noted in AKI mice with respect to healthy control mice. Controls for
the technique are stained with nonspecific IgG. (C) Time course of kidney Klotho
mRNA expression and plasma creatinine levels in folic acid-induced AKI. Kidney Klotho
mRNA is decreased even when renal function has recovered. Mean  SEM of six
animals per group. *P  0.005 versus control.
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TNFR2 for TNF (Figure 1A).8,33,34 This is
associated with tubulointerstitial inflamma-
tion characterized by a five-fold (P  0.002
versus control) increased number of intersti-
tial F4/80-positive macrophages (Figure 1B)
and by activation of the inflammation-re-
lated transcription factor NFB in tubular
cells.7,35 Klotho mRNA expression was de-
creased in experimental AKI induced by folic
acid (Figure 1C) or cisplatin (Supplemental
Figure S1). The time course was studied in
folic acid-induced AKI. Interestingly, Klotho
downregulation remained significant after
recovery of renal function (Figure 1C).
Treatment with neutralizing anti-TWEAK
antibody prevented the decrease in Klotho
mRNA and protein expression in folic ac-
id-induced AKI, suggesting a contribution
of this cytokine to the downregulation of
renal Klotho expression (Figure 2, A and
C). Absence of TWEAK in TWEAK KO
mice also prevented the reduction in renal
Klotho mRNA during AKI, compared with
wild-type (WT) mice (Figure 2B). How-
ever, the basal mRNA expression of Klotho
in untreated WT or TWEAK KO kidney
was similar.Moreover, Klotho plasma con-
centration was also reduced in folic acid-
induced AKI, and treatment with anti-
TWEAK neutralizing antibodies prevented
the decrease in Klotho plasma levels (Fig-
ure 2D). We confirmed that the decreased
renal function during AKI was significantly
improved by neutralizing anti-TWEAKan-
tibody pretreatment (Figure 3, A and B).
Moreover, inTWEAKKOmicewithAKI, re-
nal function and histologic AKI score were
preserved comparedwithWTmicewithAKI
(Supplemental Figure S2).
In Vivo Exogenous TWEAK Decreases
Renal Klotho through NFB
Activation
The beneficial effect of TWEAK blockade in preventing down-
regulation of renal Klotho expression in AKI might be a direct
effect or an indirect consequence of ameliorated tissue injury.7
Thus,weexploredwhetherTWEAKdirectlyregulatedkidneyKlotho
expression in vivo. Systemic injection of TWEAK decreased renal
Klotho mRNA levels in vivo at 4 and 24 h (Figure 4A). We have
previously shown that the kidney proinflammatory action of
TWEAK depends on NFB activation in tubular cells.7 In this
regard, Klotho downregulation induced by TWEAK was pre-
vented by treatment with the NFB inhibitor parthenolide
(PTN) (Figure 4A), suggesting that reduction of Klotho ex-
pression by TWEAK is mediated by NFB activation. We con-
firmed by Western blot that TWEAK reduced expression of
Klotho at the protein level at 24 h (Figure 4B).
TWEAK and TNF Decreases Klotho Expression in
Cultured Renal Tubular Cells
TWEAKadministrationmayhave recruited secondarymediators of
injury in vivo that lead to the decreased renal Klotho expression.
Therefore, we explored whether TWEAK and TNF, an inflamma-
tory cytokine from the same family that also activatesNFB, directly
regulate Klotho expression in cultured tubular cells.We have previ-
ously shown that both, TWEAK andTNF, increase the expression
of a variety of genes implicated in inflammation through the activa-
tionofNFB.7Thus,TWEAKandTNFincreasedthemRNAexpres-
Figure 2. Antagonism or absence of TWEAK prevented downregulation of Klotho in
renal tubulointerstitial inflammation. (A and B) The decreased total kidney Klotho
mRNA expression observed in folic acid-induced AKI at 72 hours (RT-PCR) is improved
by (A) TWEAK antagonism, using a neutralizing anti-TWEAK antibody (mean  SEM of
six animals per group; *P  0.002 versus healthy mice; #P  0.02 versus AKI; †P  0.02
versus AKIIsotype IgG) or by (B) TWEAK absence as shown by comparing WT and
TWEAK KO mice (mean  SEM of five animals per group; *P  0.005 versus WT
healthy; #P  0.03 versus WT AKI). (C) Total kidney Klotho protein, measured by
Western blot, is also reduced in AKI at 72 h, and this reduction is prevented by TWEAK
antagonism. Mean  SEM of six animals per group. *P  0.002 versus healthy mice;
#P  0.02 versus AKI; †P  0.02 versus AKIIsotype IgG. (D) Plasma levels of Klotho,
measured by ELISA, are decreased in mice with AKI at 72 hours, and this is improved
by anti-TWEAK antibody pretreatment. Mean  SEM of six animals per group. *P 
0.005 versus healthy mice; #P  0.05 versus AKI; †P  0.05 versus AKIIsotype IgG.
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sion of bona fideNFBRelA/p65 target inflammatory genes such as
MCP-1 and IL-6 (48- and 28-fold for TWEAK and 26- and 12-fold
for TNF at 3 h in renal tubular cells, P 0.05).7 Here we show that
both TWEAK and TNF decreased Klotho mRNA expression in a
dose-dependentmanner by 3 h (Figure 5, A throughC).Moreover,
TWEAK and TNF also decreased Klotho protein (Figure 5D). Fi-
nally, Klotho concentration in cell supernatants also decreased after
TWEAK treatment (Figure 5E).
TWEAK blockade with an anti-TWEAK antibody prevented
Klotho downregulation induced by TWEAK, confirming the speci-
ficity of the interaction (Figure 6A). Anti-TNFneutralizing antibod-
ies prevented TNF-induced Klotho mRNA downregulation (data
not shown). TWEAK required binding to Fn14 because the anti-
Fn14 neutralizing antibody ITEM-4 prevented TWEAK-induced
KlothomRNAdownregulation (Figure 6B).
NFB Mediates TWEAK- and TNF-induced Klotho
Downregulation
Inmurine tubular epithelial cells TWEAKandTNF increased
the DNA binding activity of NFB as assessed by electropho-
retic mobility shift assay (EMSA) (Figure 7A) and induced the
translocation of the RelA/p65 subunit from the cytoplasm to
the nucleus (Figure 7B). Degradation of IB is required for
RelA translocation to the nucleus. In tubular cells, Klotho
mRNA expression was decreased in cells transfected with a
siRNA targeting IB, indicating that Klotho expression is
regulated by NFB (Supplemental Figure S3). PTN inhibits
NFB activation by preventing the degradation of IB.36
PTN prevented RelA translocation and NFB activation in-
duced by either TWEAK or TNF (Figure 7B). Althoughmost
known actions of NFB RelA involve induction of gene tran-
scription, it may also actively repress gene expression.37 In this
regard, we observed that PTN prevented the downregulation
of Klotho mRNA expression induced by TWEAK or by TNF
(Figure 7C). Moreover, chromatin immunoprecipitation
(ChIP) assays showed RelA binding at the murine Klotho
promoter in murine proximal tubular epithelial (MCT)
cells upon TWEAK stimulation for 60 minutes (Figure 8A
and B). These results suggest that the inflammatory cyto-
kines, TWEAK and TNF, decreased Klotho expression
through NFB activation.
Histone Deacetylase Activity Is Required for
TWEAK-/TNF-decreased Klotho Expression
Histone acetylation/deacetylation is an important step in chro-
matin remodeling that plays a key role in regulation of gene
Figure 3. TWEAK neutralization improves renal function during
AKI. AKI was induced by a folic acid overdose in mice and renal
function was assessed at 72 hours measuring plasma creatinine
and BUN. (A) Plasma creatinine levels. (B) BUN. Mean  SEM of
six animals per group. *P  0.004 versus healthy mice; #P  0.04
versus AKI; †P  0.03 versus AKIIsotype IgG.
Figure 4. Systemic TWEAK injection in healthy mice decreases
renal Klotho mRNA and protein in vivo in healthy mice. TWEAK or
vehicle were injected intraperitoneally. Total kidney Klotho mRNA
and protein were decreased in a time-dependent manner in
TWEAK-injected mice, compared with vehicle-treated control
mice. This effect was reverted by pretreatment with Parthenolide
(PTN). (A) Quantitative RT-PCR analyses of renal Klotho mRNA in
mice 4 or 24 hours after TWEAK, PTN, or TWEAK/PTN. Mean 
SEM of six animals per group. *P  0.01 versus control; #P  0.05
versus TWEAK alone. (B) Total kidney Klotho protein levels in
mice treated with TWEAK and PTN for 24 hours measured by
Western blot. Mean  SEM of six animals per group. *P  0.02
versus control; #P  0.02 versus TWEAK alone.
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expression. Histone deacetylation mediated by histone
deacetylase (HDAC) generally leads to transcriptional repres-
sion and may change RelA activity from induction to repres-
sion of transcription.37,38 Thus, we tested the modulation of
TWEAK-/TNF-induced downregulation of Klotho expres-
sion by the HDAC inhibitors trichostatin A (TSA) or valproic
acid. TSA or valproic acid pretreatment prevented Klotho
downregulation induced by TWEAK or TNF (Figure 9A
and Supplemental Figure S4, respectively). Moreover, RelA
is associated with HDAC1 in nuclei of TWEAK- or TNF-
stimulated cells as assessed by immunoprecipitation (Figure
9B). ChIP assays using antibodies against acetylated histones
corroborated that TWEAK promoted his-
tone H3 and H4 deacetylation at the murine
Klotho promoter (Figure 9C).
DISCUSSION
The main finding of our study is that in
kidney cells Klotho is negatively regulated
by inflammation, and it is downregulated
by an NFB RelA-dependent mechanism.
We have identified individual inflamma-
tory cytokines such as TWEAK or TNF
that downregulate Klotho in cell culture
and in vivo. Both proinflammatory cyto-
kines signal through NFB RelA to in-
crease the expression of a variety of in-
flammatory mediators.7,39 However, in
the case of Klotho, NFB RelA appears to
downregulate gene expression in an in-
flammatory milieu. These findings may
have therapeutic implications in kidney
injury and inflammation-associated pre-
mature aging.
The Klotho gene encodes a single-pass
transmembrane protein that binds to multi-
ple FGF receptors and functions as a co-re-
ceptor for FGF23, a bone-derived hormone
that suppresses phosphate reabsorption and
vitamin D biosynthesis in the kidney. In ad-
dition, the extracellular domain of Klotho
protein is shed and secreted, potentially func-
tioning as a humoral factor. The secreted
Klotho protein can regulate multiple growth
factor signaling pathways, including insulin/
IGF-1 and Wnt, and the activity of multiple
ion channels. Klotho also protects cells and
tissues from oxidative stress, yet the precise
mechanism underlying this activity remains
to be determined. As a result, lack of Klotho
in mice results in accelerated aging.40 The
kidney is the main site of Klotho expres-
sion, and kidney injury, as corroborated
by our findings, results in reduced renal Klotho expres-
sion.25,41 We may speculate that a decreased renal expres-
sion of Klotho may have local and systemic adverse conse-
quences. Regarding potential systemic effects, reduced
kidney Klotho expression during AKI persisted beyond re-
covery of renal function and was associated with decreased
circulating Klotho. Decreased renal, circulating, and urine
Klotho was recently reported in ischemia-reperfusion-in-
duced AKI.42 Patients with kidney disease have progressive
injury to multiple organs, among them the cardiovascular
system, resulting in a mortality rate which is ten times that
of age-matched controls, resulting in effective accelerated
Figure 5. Inflammatory cytokines decrease Klotho expression in cultured tubular cells
in an NFB-dependent manner. TWEAK (A) and TNF (B) decrease Klotho mRNA
expression in a dose-dependent manner at 3 hours in MCT cells. Mean  SD of three
independent experiments. *P  0.0001 versus control; #P  0.001 versus control. (C)
Time course of TWEAK (100 ng/ml) and TNF (30 ng/ml) decreased Klotho mRNA
expression in tubular cells. Mean SD of three independent experiments. *P 0.0001
versus control. Real time RT-PCR. (D) Representative Western blot and quantification of
three independent experiments shows decreased Klotho protein in MCT cells treated
with TWEAK (100 ng/ml) or TNF (30 ng/ml). Mean  SD of three independent
experiments. *P  0.008 versus control. (E) MCT cells were treated with 100 or 50
ng/ml TWEAK for 24 hours, and Klotho levels were measured in cell supernatants by
ELISA. TWEAK decreased soluble Klotho in a dose-dependent manner. Mean  SD of
three experiments. *P  0.05 versus control; #P  0.05 versus TWEAK 50 ng/ml.
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aging.14,43 Interestingly, systemic inflammation also pro-
motes cardiovascular morbidity and mortality and has been
associated with other age-dependent diseases such as osteo-
porosis and dementia.44,45 Locally, a reduction of Klotho
expression contributed to progression of kidney failure; al-
though its overexpression ameliorated renal injury in a
mouse model.46 Ad-Klotho gene transfer improved serum
creatinine and reduced renal apoptosis induced by isch-
emia-reperfusion in rats.22 Klotho transfection reduced
H2O2-induced tubular cell apoptosis in culture.29 Klotho is
also expressed in extrarenal cells. Thus, Klotho expression is
reduced in human CD4 lymphocytes from aged patients.47
Our results show that TWEAK and TNF induce Klotho
downregulation in a dose-dependent fashion in cultured
renal cells, that TWEAK decreases kidney Klotho in vivo,
and that targeting TWEAK prevents Klotho downregulation
during kidney injury. Evidence suggesting that RelA activa-
tion is necessary for TWEAK- and TNF- induced Klotho
repression includes the following: (1) IB downregulation
by siRNA, a maneuver that allows RelA translocation to
nuclei, promoted Klotho downregulation, (2) an inhibitor
of RelA activation, PTN, prevented TWEAK- and TNF-
induced Klotho downregulation, (3) the temporal pattern
of Klotho repression observed is consistent with that of RelA
activation induced by TWEAK and TNF, (4), and RelA is
bound to Klotho promoter in MCT cells stimulated with
TWEAK.7,36 NFB-mediated downregulation of gene ex-
pression had previously been observed for TNF, such as
downregulation of argininosuccinate synthase, endothelial
nitric oxide synthase, and Bmp4 gene expression.48–50 How-
ever, it had not been observed for TWEAK. TWEAK acti-
vates at 24 h a subset of NFB2 protein complexes that are
different from those observed after TNF stimulation.9,51
However, both cytokines share the early activation of RelA-
containing NFB complexes.7,9,51 The fact that both
TWEAK and TNF downregulate Klotho and that this is an
early event argues against an involvement of NFB2, which
is only activated by TWEAK and whose activation takes
place after changes in Klotho mRNA have already occurred.
Themain“switch” inNFBactivation is cytoplasmicand leads
to the nuclear accumulation of NFB proteins. In addition, re-
cruitment of NFB to chromatin is regulated in a promoter-spe-
cific manner. This kinetic complexity in NFB-dependent gene
induction is dependent on simultaneously activated pathways
and transcription factors.52 In addition to gene-specific factors
there are stimulus-specific factors that determine the activator or
repressor activity of NFB on gene transcription.37 Thus, NFB
induced by noncytokine cytotoxic stimuli is functionally distinct
from NFB induced by TNF: the first is an active repressor of
antiapoptotic gene expression, whereas the latter promotes anti-
apoptotic gene expression.37 There are different mechanisms for
p65/RelA-dependent gene repression.Recently, it has becomeap-
parent the importance of HDAC activity. HDAC activity is re-
quired for p65/RelA-dependent repression of PPAR in human
keratinocytes, of antiapoptotic genes in fibroblasts, and of PDGF
in smooth muscle cells.37,53,54 We observed that TWEAK and
TNF increasednuclearRelAassociationwithnuclearHDAC1at
the same time that Klotho expression was decreased in tubular
cells. This result suggested that TWEAK- and TNF-induced
Klotho downregulation could be mediated by HDAC activity. In
this regard, we observed thatHDAC inhibitors, TSA and valproic
acid, prevented repression of Klotho induced by TWEAK or
TNF. Furthermore, TWEAK induces histone H3 and H4
deacetylation at the murine Klotho promoter in renal tubular
cells.
Although TWEAK targeting by either neutralizing anti-
bodies or in TWEAK KO mice preserved kidney Klotho ex-
pression and circulating Klotho levels and also preserved
renal function, our studies do not allow us to conclude that
Klotho preservation has a role in renal function improve-
ment. However we can speculate on a nephroprotective role
of Klotho based on the beneficial effect of Klotho overex-
pression on progressive renal injury55 and in AKI.42,56
In summary, the inflammatory cytokines TWEAK and TNF
downregulate Klotho in renal tubular cells through an NFB-
dependent mechanism. These results are of interest to kidney in-
jury and to the accelerated aging observed in uremic patients.
They identify an additional adverse consequence of NFB activa-
tion in kidney injury. In this regard, our resultsmay be relevant to
design therapeutic approaches to regulate Klotho expression.
Figure 6. Fn14 mediates TWEAK-induced Klotho downregulation in
cultured tubular cells. (A) A neutralizing anti-TWEAK antibody (10 g/
ml) rescued Klotho levels in MCT cells treated with 100 ng/ml TWEAK
for 3 hours. Mean SD of three independent experiments. *P 0.002
versus control; #P  0.02 versus TWEAK alone; †P  0.006 versus
TWEAKIsotype IgG. (B) ITEM-4 (10 g/ml), a neutralizing anti-Fn14
antibody, prevented Klotho downregulation induced by TWEAK in
MCT cells, suggesting that this effect of TWEAK is mediated through
Fn14 binding. Mean  SD of three independent experiments. *P 
0.005 versus control; #P  0.02 versus TWEAK alone.
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CONCISE METHODS
Cells and Reagents
MCTs were cultured in RPMI 1640, 10% heat-inactivated FBS, 2 mM
glutamine, 100 U/ml penicillin, and 100 g/ml streptomycin, in 5%
CO2 at 37°C.7
RPMI-1640,penicillin, streptomycin,andtrypsin-EDTAwere fromBio-
Whittaker (Waltham,Massachusetts), FBS fromLife Technologies (Carls-
bad, California), and recombinant human
TWEAK from Chemicon, Millipore (Billerica,
Massachusetts). Anti-TWEAK monoclonal anti-
body (clone P2D10) and specific isotype control
(cloneP1.17) (BiogenIdec)wereusedat10g/ml.
ITEM-4, neutralizing anti-Fn14 antibody (eBio-
science, San Diego, California) was used at 10g/
ml. Anti-TNF polyclonal antibody was used at 3
g/ml (BioLegend, San Diego, California). PTN
(Sigma, St. Louis, Missouri) at 10 M inhibits
NFB activation inMCT cells without decreasing
cell viability.7 HDAC inhibitors, TSA (Upstate
Biotechnology, Millipore) and valproic acid
(Sigma), were used at 100 ng/ml and 3 mM, re-
spectively. Klotho concentration in cell superna-
tants and mice plasma was determined with the
E97757Mu ELISA Kit (USCNK, Wuhan,
P.R.China).
Animal Models
Studies were conducted in accord with the NIH
Guide for the Care and Use of Laboratory Ani-
mals. C57/BL6 mice (12 to 14 weeks old) (IFFA-
CREDO, Barcelona, Spain) were treated with 70
g/mouse PTN or its vehicle (0.05%DMSO) and
0.75 g/mouse of TWEAK or saline. Treatment
and control groups (n  6) were as follows: 1)
PTNfollowedbyTWEAK,2)vehicle (DMSO) fol-
lowed byTWEAK, 3) PTN followed by saline, and
4) vehicle (DMSO) followed by saline. PTN was
injected 24 h before that TWEAK injection and
TWEAK 4 or 24 h before sacrifice. The dose of
TWEAK was calculated based on in vitro experi-
ments for an extracellular volume of 7.5 ml/
mouse. The dose of PTNwas established based on
previous experience.7
Folic acid nephropathy is a classicalmodel of
AKI.7,57–59 C57/BL6 mice (12 to 14 weeks old)
received a single intraperitoneally injection of
folic acid (Sigma) 250 mg/kg in 0.3 M sodium
bicarbonate or vehicle, and mice were killed 24
or 72 h or 7 d later.7 Mice were dosed intraperi-
toneally with either 200 g neutralizing anti-
TWEAK mAb (clone P2D10, Biogen Idec)7 or
200 g isotype IgG (mouse IgG2a, clone P1.17,
Biogen Idec) (n 6 per group). In another set of
experiment, TWEAK KO (Biogen Idec)60 mice
on theC57Bl/6 background strain received intraperitoneally folic acid
injection, and they were killed 72 h later (n 5 per group).
Cisplatin is a nephrotoxic routinely used in clinical in cancer treatment.
C57/BL6mice (12 to 14weeks old) received a single intraperitoneally injec-
tion of cisplatin (Sigma, 20mg/kg in saline) or vehicle, andmicewere killed
72h later (n 5per group). Thedosewas derived frompreliminary studies
inourmice colony.Meanplasmacreatinine in cisplatinAKImicewas0.8
0.1mg/dl.
Figure 7. PTN prevents Klotho downregulation induced by TNF or TWEAK in cul-
tured tubular cells. (A) TNF or TWEAK promoted DNA binding of NFB complexes as
assessed by EMSA. Quantification (mean  SD) and representative EMSA of three
independent experiments. *P  0.05 versus control. (B) TNF or TWEAK promote the
translocation of the RelA/p65 protein to the nucleus at 60 minutes in tubular cells. This
is prevented by PTN. Nuclear translocation of NFB subunits is required for DNA
binding. Images representative of three independent experiments. Confocal micros-
copy where RelA is green and propidium iodide (nuclei) is orange (magnification,
320). (C) The NFB inhibitor PTN prevents TWEAK- and TNF-induced downregulation
of Klotho mRNA in cultured MCT cells at 3 hours. Mean  SD of three independent
experiments. *P  0.0001 versus control; #P  0.0001 versus cytokine alone.
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The kidneys were perfused in situwith cold saline before removal.
One kidney was snap-frozen in liquid nitrogen for RNA and protein
studies, and the other was fixed and paraffin-embedded.
Immunohistochemistry
Immunohistochemistry was carried out as described previously in paraffin-
embedded tissue sections 5mthick.7 Primary antibodywas rat polyclonal
anti-F4/80antigen (1:50, Serotec). Sectionswere counterstainedwithCaraz-
zi‘shematoxylin.Negativecontrols includedincubationwithanonspecificIg
of the same isotype as the primary antibody. The total number of F4/80-
positive macrophages was quantitated in 20 randomly chosen fields (40)
using Image-Pro Plus software (Media Cybernetics, Silver Spring, MD).
Sampleswere examined in a blindedmanner.
Tubularinjurywasevaluatedinhematoxylin-eosinsectionsbyanoutside
pathologist(J.B.)blindedtothenatureofthesamples.Evidenceforcell injury
(loss of brush border, vacuolization), cell desquamation, focal calcification,
tubulardilation,mitosisandsignsofregenerationwerescoredinasemiquan-
titative scale from0 to 3, and results from each itemwere added to yield the
histologicAKI score,whichhad amaximal value of 21.
Quantitative Reverse
Transcription-PCR
Onemicrogram RNA isolated with Trizol (Invitrogen, Carlsbad, Cal-
ifornia) was reverse-transcribed with High Capacity cDNA Archive Kit
and real-time PCR was performed on a ABI Prism 7500 PCR system (Ap-
plied Biosystems, Foster City, California) using the DeltaDelta Ctmethod.7
Expression levels are given as ratios to GAPDH. Predeveloped primer and
probe assays were obtained for murine GAPDH and Klotho (Applied Bio-
systems).
Western Blot
Cell samples or tissue were homogenized in lysis buffer (50 mM
TrisHCl, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.2% Triton
X-100, 0.3% NP-40, 0.1 mM PMSF, and 1 g/ml pepstatin A) and
then separated by 10%SDS-PAGEunder reduc-
ing conditions. After electrophoresis, samples
were transferred to PVDF membranes (Milli-
pore, Bedford,Massachusetts), blockedwith 5%
skimmed milk in PBS/0.5% vol/vol Tween 20
for 1 h, washed with PBS/Tween, and incubated
with rabbit polyclonal anti-Klotho (1:500, Cal-
biochem, La Jolla, California) or goat polyclonal
anti-HDAC1 (1/500, SantaCruz Biotechnology,
Santa Cruz, California). Antibodies were di-
luted in 5%milk PBS/Tween. Blots were washed
with PBS/Tween and incubated with appropri-
ate horseradish peroxidase-conjugated second-
ary antibody (1:2000, Amersham, Aylesbury,
UK). After washing with PBS/Tween the blots
were developed with the chemiluminescence
method (ECL, Amersham). Blots were then
probed with mouse monoclonal anti--tubulin
antibody (1:2000, Sigma), and levels of expres-
sion were corrected for minor differences in
loading.
EMSA
Cells were resuspended in buffer A and homogenized.7 Nuclei and
cytosolic fractions were separated by centrifugation at 1000 g for 10
minutes. Nuclei (pellet) were washed twice in buffer A and resus-
pended in the same buffer, with a final concentration of 0.39 mol/L
KCl. Nuclei were extracted for 1 hour at 4°C and centrifuged at
100,000 g for 30 minutes. Supernatants were dialyzed in buffer C and
then cleared by centrifugation and stored at80°C. The protein con-
centration was determined by the bicinchonicic acid method. EMSA
was carried out as described previously.7
Immunostaining
Cells plated onto Labtek slides were fixed in 4% paraformaldehyde
and permeabilized in 0.2% Triton X-100/PBS, washed in PBS, and
incubated with rabbit polyclonal anti-RelA (1:75), followed by
FITC secondary antibody (1:200, Sigma). Nuclei were counter-
stained with propidium iodide.
Immunoprecipitation
Nuclear extracts of MCT cells treated with TWEAK or TNF was ob-
tained as described previously.7 One hundred micrograms of nuclear
extract was immunoprecipitated. In brief, each sample was precleared
with 90l protein A/G–Sepharose beads (Santa Cruz Biotechnology).
Precleared nuclear extracts were incubated with 3 g of rabbit poly-
clonal anti-RelA (Santa Cruz Biotechnology) overnight at 4°C with
gentle rotation. Next, extracts were incubated with 20 l of bead sus-
pension for 2 h at 4°C with rotating. The complexes were then centri-
fuged at 4°C for 1 minute, and the beads were washed four times with
100 l buffer A.7 The beads were then resuspended in SDS sample
buffer, boiled for 5 minutes, and analyzed on SDS-10% polyacryl-
amide gels as described above.
Figure 8. TWEAK induces RelA binding to the Klotho promoter in cultured tubular
cells. (A) Region 1; (B) region 2. MCT cells were stimulated with TWEAK for 60 minutes,
and ChIP analyses were performed using an anti-RelA antibody. Promoter copy num-
ber was quantified by real-time PCR in duplicate using two specific primers that amplify
two different NFB binding sites of the Klotho promoter. Normal rabbit IgG was used
as negative control for the specificity of the immunoprecipitation (intraperitoneally). As
a positive control, aliquots of chromatin fragments obtained before intraperitoneally
were also subjected to RT-PCR analysis (Input). Immunoprecipitated DNA with RelA
binding was normalized to a 100-fold dilution of input chromatin. Data are expressed
as fold enrichment of RelA binding compared with negative control antibody (normal
rabbit IgG). n  4; *P  0.04 versus control.
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ChIP assay
ChIP assays using 0.5 to 1  106 cells per sample were performed as
described previously61 using 10 g/ml anti-AcH3, anti-AcH4, and
anti-RelA (Upstate Biotechnology) antibodies. Normal IgG was used
as negative control. In brief, cells fixed with 1% formaldehyde were
lysed in SDS-lysis buffer (1% SDS, 10 mM
EDTA, 50mMTris-HCl, pH 8.1) and sonicated.
Chromatin was diluted into ChIP dilution buf-
fer (0.01% SDS, 1.1% Triton X-100, 1.2 mM
EDTA, 16.7 mM Tris-HCl, pH 8.1, 167 mM
NaCl) and incubated with the antibodies over-
night at 4°C. Antibody-chromatin complexes
were precipitatedwith salmon spermDNA/Pro-
tein A–Agarose beads (Upstate Biotechnology),
washed, and eluted from the beads using elu-
tion buffer (1% SDS, 0.1 M NaHCO3). After
crosslink reversal and proteinase K treatment,
DNA was extracted with phenol-chloroform,
and ethanol was precipitated. DNA immuno-
precipitated from 1 l eluted DNA was ana-
lyzed in duplicate by real-time PCR. Primers
were designed to amplify specific NFB re-
gions (regions 1 and 2) at promoter of the
Klotho gene, identified by TFSEARCH: Searching
Transcription Factor Binding Sites (http://
molsun1.cbrc.aist.go.jp/research/db/TFSEARCH.
html). Primers for each promoter are listed in
Supplemental Table S1. Aliquots of chroma-
tin obtained before immunoprecipitation
were analyzed as input control. Results are
presented as fold enrichment of precipitated
DNA associated with a given histone modifi-
cation or RelA binding, relative to a 1/100 di-
lution of input chromatin.
siRNA Transfection
Cells were seeded in six-well plates and trans-
fected on the following day with 20 nM siRNA
using Lipofectamine 2000 reagent (Invitro-
gen).62 After 48 h, the transfected cells were
harvested for Western blot or PCR analysis.
siRNA were synthesized by Santa Cruz Bio-
technology.
Statistical Analysis
Statistical analysis was performed using SPSS
11.0 statistical software. Results are expressed as
mean  SD. Significance at the P  0.05 level
was assessed by t test for two groups of data and
ANOVA for three or more groups.
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